Completing MedWatch Forms for Administering Bamlanivimab

This ASPR TRACIE TA response document includes comments from ASPR TRACIE Subject Matter Expert Cadre members regarding whether healthcare providers are required to fill out MedWatch forms to document doses of Bamlanivimab that were administered to patients (even if they did not have adverse effects).
Favorite:
You must Login to add a comment
  • This item doesn't have any comments

Enter your email address to receive important announcements and updates through the ASPR TRACIE Listserv.